FFNTF (4Front Ventures) ROE %: 0.00% (As of Sep. 2024)


FFNTF 4Front Ventures Corp FFNTF
10 GF Score
Price $0.00
View Full Analysis

What is 4Front Ventures ROE %?

4Front Ventures FFNTF -90.00% 10 ROE % is 0.00% as of Sep. 2024. GuruFocus rates FFNTF with a GF Score™ of 10/100.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. 4Front Ventures's annualized net income for the quarter that ended in Sep. 2024 was $-25.61 Mil. 4Front Ventures's average Total Stockholders Equity over the quarter that ended in Sep. 2024 was $-46.60 Mil. Therefore, 4Front Ventures's annualized ROE % for the quarter that ended in Sep. 2024 was N/A%.

The historical rank and industry rank for 4Front Ventures's ROE % or its related term are showing as below:

FFNTF's ROE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.865
* Ranked among companies with meaningful ROE % only.

4Front Ventures  (OTCPK:FFNTF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-25.612/-46.6035
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-25.612 / 68.528)*(68.528 / 278.5365)*(278.5365 / -46.6035)
=Net Margin %*Asset Turnover*Equity Multiplier
=-37.37 %*0.246*N/A
=ROA %*Equity Multiplier
=-9.19 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-25.612/-46.6035
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-25.612 / -25.852) * (-25.852 / -26.048) * (-26.048 / 68.528) * (68.528 / 278.5365) * (278.5365 / -46.6035)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9907 * 0.9925 * -38.01 % * 0.246 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


4Front Ventures ROE % Related Terms


4Front Ventures ROE % Historical Data

* Premium members only.

The historical data trend for 4Front Ventures's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4Front Ventures ROE % Chart

4Front Ventures Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -499.04 -292.37 -96.24 -142.72 0.00

4Front Ventures Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FFNTF vs CRYM, PNXP, SKYI: ROE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, 4Front Ventures's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4Front Ventures ROE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, 4Front Ventures's ROE % distribution charts can be found below:

* The bar in red indicates where 4Front Ventures's ROE % falls into.


FFNTF
10GF Score
4Front Ventures Corp FFNTF
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4Front Ventures ROE % Calculation

4Front Ventures's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-91.647/( (28.258+-51.502)/ 2 )
=-91.647/-11.622
=N/A %

4Front Ventures's annualized ROE % for the quarter that ended in Sep. 2024 is calculated as

ROE %=Net Income (Q: Sep. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Sep. 2024 ))/ count )
=-25.612/( (-44.646+-48.561)/ 2 )
=-25.612/-46.6035
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
4Front Ventures (FFNTF) has a ROE % of 0.00% as of Sep. 2024. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on 4Front Ventures and its competitors.
Is 4Front Ventures' ROE % too high?
4Front Ventures' current ROE % is 0.00%. Overall, 4Front Ventures has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does 4Front Ventures' ROE % compare to CRYM and PNXP?
4Front Ventures' ROE % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROE % is 5.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on 4Front Ventures and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4Front Ventures's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4Front Ventures stock overvalued right now?
4Front Ventures (FFNTF) has a current ROE % of 0.00%. The current ROE % is 0.00%. 4Front Ventures' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For 4Front Ventures (FFNTF), the current ROE % is 0.00% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

4Front Ventures Business Description

Address 7010 E. Chauncey Lane, Suite 235, Phoenix, AZ, USA, 85054
4Front Ventures Corp is a Canadian-based company. It is engaged in the cultivation, processing, extracting, manufacturing, and distribution of cannabis products. It operates in two segments: THC Cannabis and CBD Wellness. The THC Cannabis segment engages in the production and cultivation of THC cannabis, manufacturing and distribution of cannabis products to owned dispensaries and third-party retail customers. The CBD Wellness segment encompasses the production and sale of CBD products to third-party customers.
10GF Score

Get the complete analysis for FFNTF

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price